Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design of Experiments (DoE)-Optimized Polymeric Oxytocin Nanoparticles for Enhanced Nose-to-Brain Delivery.

Small (Weinheim an der Bergstrasse, Germany)·2025
Same author

Cortico-striatal action control inherent of opponent cognitive-motivational styles.

eLife·2025
Same author

Cortico-striatal action control inherent of opponent cognitive-motivational styles.

bioRxiv : the preprint server for biology·2024
Same author

Neuro-Immune Modulation of Cholinergic Signaling in an Addiction Vulnerability Trait.

eNeuro·2023
Same author

Basal Forebrain Chemogenetic Inhibition Converts the Attentional Control Mode of Goal-Trackers to That of Sign-Trackers.

eNeuro·2023
Same author

Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease.

Progress in brain research·2022

Related Experiment Video

Updated: May 21, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Revitalizing psychiatric drug discovery.

Martin Sarter1, Mark Tricklebank

  • 1Department of Psychology, University of Michigan, 530 Church Street, 4032 East Hall, Ann Arbor, Michigan 48103-8862, USA. msarter@umich.edu

Nature Reviews. Drug Discovery
|June 2, 2012
PubMed
Summary

Closing the systems neuroscience gap is crucial for psychiatric drug discovery. This approach aims to improve the success rates of novel psychiatric medications in clinical trials.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Psychiatric drug discovery faces low clinical success rates.
  • Novel mechanisms of action are needed for effective treatments.
  • A gap exists between systems neuroscience and drug development.

Purpose of the Study:

  • To highlight the necessity of integrating systems neuroscience into psychiatric drug discovery.
  • To propose strategies for bridging the gap between neuroscience research and clinical application.
  • To enhance the development of psychiatric medications with improved efficacy.

Main Methods:

  • Review of current psychiatric drug discovery pipelines.
  • Analysis of systems neuroscience methodologies.
  • Identification of potential integration points between neuroscience and pharmacology.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

Related Experiment Videos

Last Updated: May 21, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

Main Results:

  • Systems neuroscience offers novel targets and biomarkers for psychiatric disorders.
  • Integration can lead to more precise and effective drug candidates.
  • Bridging the gap requires interdisciplinary collaboration.

Conclusions:

  • Closing the systems neuroscience gap is essential for advancing psychiatric drug discovery.
  • A systems neuroscience-informed approach promises higher clinical success rates for novel psychiatric drugs.
  • Future research should focus on translational strategies linking basic neuroscience to clinical development.